Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of birtamimab plus standard of care versus placebo plus standard of care in Mayo stage IV AL amyloidosis
2021-000037-14Phase 3Active
- Sponsor
- Prothena Corporation
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Birtamimab plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Time to all-cause mortality during the Double-blind Phase. Started Apr 2021; status: active.
02
Drugs
birtamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2021-000037-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000037-14.